Publicaciones en colaboración con investigadores/as de Hospital de la Santa Creu i Sant Pau (16)

2021

  1. The prevention of relapses in first episodes of schizophrenia: The 2EPs Project, background, rationale and study design

    Revista de Psiquiatria y Salud Mental, Vol. 14, Núm. 3, pp. 164-176

  2. The usefulness of Olanzapine plasma concentrations in monitoring treatment efficacy and metabolic disturbances in first-episode psychosis

    Psychopharmacology, Vol. 238, Núm. 3, pp. 665-676

2020

  1. Personalized medicine begins with the phenotype: identifying antipsychotic response phenotypes in a first-episode psychosis cohort

    Acta Psychiatrica Scandinavica, Vol. 141, Núm. 6, pp. 541-552

2019

  1. Patient characteristics driving clinical utility in psychiatric pharmacogenetics: a reanalysis from the AB-GEN multicentric trial

    Journal of Neural Transmission, Vol. 126, Núm. 1, pp. 95-99

2018

  1. Evolution of metabolic risk factors over a two-year period in a cohort of first episodes of psychosis

    Schizophrenia Research, Vol. 193, pp. 188-196

2017

  1. Intuitive pharmacogenetic dosing of risperidone according to CYP2D6 phenotype extrapolated from genotype in a cohort of first episode psychosis patients

    European Neuropsychopharmacology, Vol. 27, Núm. 7, pp. 647-656

  2. Persistent negative symptoms in first-episode psychosis: Early cognitive and social functioning correlates and differences between early and adult onset

    Journal of Clinical Psychiatry, Vol. 78, Núm. 9, pp. 1414-1422

2016

  1. A Pharmacovigilance Study in First Episode of Psychosis: Psychopharmacological Interventions and Safety Profiles in the PEPs Project

    International Journal of Neuropsychopharmacology, Vol. 19, Núm. 4

2014

  1. Replication of previous genome-wide association studies of psychiatric diseases in a large schizophrenia case-control sample from Spain

    Schizophrenia Research, Vol. 159, Núm. 1, pp. 107-113

2012

  1. Recommendations for the prevention and management of suicidal behaviour

    Revista de Psiquiatria y Salud Mental, Vol. 5, Núm. 1, pp. 8-23

2010

  1. Rendimiento psicométrico de la sexta versión del Addiction Severity Index en español (ASI-6)

    Psicothema, Vol. 22, Núm. 3, pp. 513-519

2009

  1. Recovery from schizophrenia: Results from a 1-year follow-up observational study of patients in symptomatic remission

    Schizophrenia Research, Vol. 115, Núm. 1, pp. 58-66

2008

  1. The prevalence of metabolic syndrome in patients with bipolar disorder

    Journal of Affective Disorders, Vol. 106, Núm. 1-2, pp. 197-201

2005

  1. Safety and effectiveness of olanzapine in monotherapy: A multivariate analysis of a naturalistic study

    Progress in Neuro-Psychopharmacology and Biological Psychiatry, Vol. 29, Núm. 6, pp. 944-951

  2. Safety, effectiveness, and patterns of use of olanzapine in acute schizophrenia: A multivariate analysis of a large naturalistic study in the hospital setting

    Medicina Clinica, Vol. 124, Núm. 13, pp. 481-486

2003

  1. Safety and effectiveness of olanzapine versus conventional antipsychotics in the acute treatment of first-episode schizophrenic inpatients

    Progress in Neuro-Psychopharmacology and Biological Psychiatry, Vol. 27, Núm. 3, pp. 473-481